All

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
2 July 2020

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

OSS, Netherlands-Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration...

Read more
CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS
2 July 2020

CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS

(BOSTON) – CARB-X announced today that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05...

Read more
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
25 June 2020

Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read the press release
MedinCell announces the great success of its capital increase and raises 15.6 M€
17 June 2020

MedinCell announces the great success of its capital increase and raises 15.6 M€

MedinCell (FR0004065605 - MEDCL), a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas (the...

Read more
Transfergo raises $10M additional funding, launches in 11 new markets
16 June 2020

Transfergo raises $10M additional funding, launches in 11 new markets

TransferGo, the London-based international money transfer service, has raised another $10 million in funding, as it discloses that its customer numbers have surpassed two...

Read more
Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder
3 April 2020

Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders,...

Read the press release
MOVE’N SEE raises funds with Seventure Partners and its Sport & Performance Capital fund
11 March 2020

MOVE’N SEE raises funds with Seventure Partners and its Sport & Performance Capital fund

World leader in automatic cameramen robots for individual athletes and scene, MOVE ‘N SEE has just achieved a fundraising to extend its offer to 200 sports. This offer now...

Read the press release
Scipio bioscience raises €6.0 M Series A financing
25 February 2020

Scipio bioscience raises €6.0 M Series A financing

Scipio bioscience, a Paris-based biotechnology company, developing a new generation of single-cell sequencing solutions, announces today that it has secured a €6.0 M Series A...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse